The companies operating in the non-muscle invasive bladder
cancer market are working toward tapping the unexplored geographies
to widen their consumer base. They are also looking forward to
upgradation of existing courses of treatment for non-muscle
cancer.
WILMINGTON, Del., July 29,
2024 /PRNewswire/ -- The global non-muscle
invasive bladder cancer market is poised for impressive growth.
TMR speculates a whopping 21% CAGR for this ecosystem in the
forthcoming decade. By the end of 2034, a market value of
US$ 21.1 billion is projected for
this industry. In 2023, the market was valued at US$ 2.6 billion.
Non-muscle invasive bladder cancer (NMIBC) is referred to as
cancer located in tissue lining the bladder's inner surface. The
bladder muscle is not playing role over there. Bladder cancer is
more prevalent in men as compared to women. It is also common with
aging. It is generally seen in age group of 75-84.
Bladder is where body stores urine prior to leaving it. It is a
hollow organ in pelvis with muscular, flexible walls. It can get
smaller or bigger as per quantity of urine. Urine reaches the
bladder through ureters. They push urine through a tube called
urethra. Growing incidence of non-muscle invasive bladder cancer
worldwide is thus driving the non-muscle invasive bladder cancer
market.
Request a PDF Sample of this Report Now!
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86334
Bladder cancer is amongst the top 10 most prevalent cancers
worldwide. Moreover, it has been reported that majority of newly
diagnosed bladder cancer cases are non-muscle invasive bladder
cancers (NMIBC). They are characterized by the cancer cells getting
confined to the bladder's inner lining. The governments across the
globe are extensively spending on intravesical anti-cancer
therapies such as BCG (live attenuated bacteria meant for
stimulating an immune response against the cancer cells) or
chemotherapy.
Researchers are also investing in maintenance therapy, so that
risk of recurrence can be reduced. Regular cystoscopies are also
prescribed in order to monitor regarding recurrence. Additional
treatments are initiated on detection of new tumors. Increase in
healthcare spending by governments as mentioned above is thus
expanding the non-muscle invasive bladder cancer market size.
Key Takeaways from the Market Study
- The global non-muscle invasive bladder cancer market is slated
to be valued at US$ 3.1 billion in
2024.
- From 2024 to 2034, the market for non-muscle invasive bladder
cancer is slated to grow 6.7x.
- By treatment type, chemotherapy is expected to remain a
prominent option for patients.
- Treatment for both low grade and high grade bladder cancers are
expected to remain elevated.
- Hospital pharmacies are the primary sales points for availing
non-invasive muscle bladder cancer treatment drugs.
Key Drivers and Trends
- Research states that bladder cancer is the 13th
leading cause of mortality due to cancer. Non-muscle invasive
variants represent three-fourth cases and have a higher recurrence
rate.
- As per the American Cancer Society, 83,190 new-fangled
cases of bladder cancer and 16,840 fatalities from bladder
cancer have been recorded as of now. It further states that 30% of
bladder cancers spread to the deeper layers of bladder wall but are
only in bladder.
- In the rest of the cases, cancer spreads to adjoining lymph
nodes/tissues outside the bladder. In 5% of cases, it spreads to
the distant parts of body on being located first. The need to
combat non-muscle invasive bladder cancer is thus contributing to
non-muscle invasive bladder cancer market growth.
Non-muscle Invasive Bladder Cancer Market Report
Scope:
Report
Coverage
|
Details
|
Forecast
Period
|
2024-2034
|
Base
Year
|
2020-2022
|
Size in 2023
|
US$ 2.6 Bn
|
Forecast (Value) in
2034
|
US$ 21.1 Bn
|
Growth Rate
(CAGR)
|
21.4 %
|
No. of
Pages
|
165
Pages
|
Segments
covered
|
By Treatment Type, By
Cancer Type, By Distribution Channel, By Region
|
Unlock Growth Potential in Your Industry! Download PDF
Brochure:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86334
Regional Profile
- North America is projected to
lead the non-invasive bladder cancer treatment landscape in 2024
and the status quo is expected to remain unchanged during the
forecast period. This is attributed to availability of
technologically advanced therapeutic and diagnostic methods in
the U.S. and conducive reimbursement policies.
- Asia Pacific's significant
non-muscle invasive bladder cancer market share is ascribed to rise
in incidence of bladder cancer in countries like China and increased accessibility to
cutting-edge products and treatments.
- Europe's increasing demand for
treatment of muscle invasive bladder cancer is due to growing
acceptance of minimally-invasive techniques, rising awareness about
early diagnosis and treatment, and increased R&D efforts in
this field.
Competitive Landscape
Key participants in the invasive bladder cancer landscape are
engaging in inorganic modes of expansion to strengthen their
position. For instance, In June 2022,
Cipla inked a distribution agreement with Roche Products
(India) Pvt. Ltd. in order to
expand scope of partnership of including marketing as well as
distribution of the latter's branded oncology drugs.
Leading Players offering Non-invasive Muscle Bladder Cancer
Treatment
- TARIS Biomedical LLC
- Merck & Co. Inc.
- Herantis Pharma Oyj
- Viventia Bio Inc.
- Telormedix SA
- Ferring B.V.
- Altor BioScience Corporation
- Novartis AG
- Pfizer Inc.
- GSK plc
- Sanofi S.A.
- Eli Lilly and Company
- AstraZeneca
Key Developments
- In July
2022, AstraZeneca expanded its portfolio pertaining
to hematological cancers by completing acquisition of TeneTwo along
with its clinical stage T-cell engager.
Key Segments Profiled
Treatment Type
- Immunotherapy
- Chemotherapy
- Targeted Therapy
Cancer Type
- Low Grade Bladder Cancer
- High Grade Bladder Cancer
End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase the Report for Market-Driven Insights:
https://www.transparencymarketresearch.com/checkout.php?rep_id=86334<ype=S
More Trending Report by Transparency Market Research:
- Low Endotoxin Gelatin Market – The
global Low Endotoxin Gelatin market , valued at USD 880.6 million in 2023, is projected to grow
at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2034.
This growth trajectory is expected to drive the market's value to
approximately USD 1.7 billion by the
end of 2034.
- Lucid Dreaming Devices Market – In 2023, the
global Lucid Dreaming Devices market was valued at USD 113.7 million. The market is anticipated to
grow at a CAGR of 5.1% from 2024 to 2034, reaching an
estimated USD 196.8 million by
2034.
- Durable Medical Equipment Market –
Durable Medical Equipment (DME) market, valued
at USD 153.1 billion in 2018, is
forecasted to grow at a CAGR of 6.2% from 2019 to
2027.
- Healthcare Automation Market – The
Healthcare Automation market, valued at USD
36.9 billion in 2020, is expected to grow at a robust
CAGR of 8.4% from 2021 to 2028. By the end of 2028, the
market is projected to exceed USD 88.9
billion.
About Transparency Market Research
Transparency Market Research, a global market
research company registered at Wilmington, Delaware, United States, provides custom research and
consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights
for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses
information.
Our data repository is continuously updated and revised by a
team of research experts, so that it always reflects the latest
trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data
sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington,
Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow
Us: LinkedIn| Twitter| Blog | YouTube
Logo -
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/non-muscle-invasive-bladder-cancer-market-to-reach-us-21-1-billion-by-2034-with-a-projected-21-cagr--exclusive-report-by-transparency-market-research-inc-302208697.html
SOURCE Transparency Market Research